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Abstract
Background: Fra-1 (fosl1) belongs to the activator protein1 (AP-1) family inducing IL-11 expression in oxidative stress
condition. IL-11 plays a pivotal role in protecting epithelial barriers integrity. In this study, we investigated the Fra-1
gene expression in the inflamed mucosa of patients with ulcerative colitis (UC) as well as its relation to IL-11 expression.
Materials and methods: We enrolled 20 patients and 20 healthy controls with definite UC based on the clinical criteria.
Fra-1 gene expression in inflamed and non-inflamed colonic biopsies was determined by real-time polymerase chain
reaction (RT-PCR). The IL-11 protein concentration was measured by Enzyme-Linked Immunosorbent Assay (ELISA)
method. Pearson correlation was applied to calculate the relation between Fra-1 and IL-11.
Results: An increased level of Fra-1 gene expression was observed in patients with mild ulcerative colitis. The protein
concentration of IL-11 was also increased in mild UC patients. Conversely, a significant decrease of IL-11 protein level was
detected in severe UC patients compared to control group.
Conclusion: Oxidative stress in inflamed intestinal biopsies can induce fra-1 gene expression. Our findings suggest that
Fra-1 transcription factor leads to the production of IL-11 protein in UC patients.
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Background
The inflammatory bowel diseases (IBDs) consist of a wide
range of disorders, like ulcerative colitis (UC), beginning
in early adulthood and affecting the remaining life-span
[1, 2]. UC is pathologically diagnosed by inflammation
and injury in the gastrointestinal tract. Various factors are
involved in its pathogenesis [3]. Despite extensive investi-
gations on patients and experimental models, the main
causes of UC, in terms of aetiology have not been under-
stood [4]. Recent investigations have reported that oxida-
tive stress plays crucial roles in the pathogenesis of UC
[5]. The release of reactive oxygen species (ROS) accom-
panied by up-regulation of proinflammatory cytokines in
intestinal inflammation which leads to activation of vari-
ous intracellular pathways, such as mitogen-activated
protein kinase (MAPK), signal transducer and activator of
transcription 3 (STAT3) [6–8]. The activator protein1
(AP-1) family is an intracellular factor modulated by
MAPK pathway. AP-1 is a homodimer or heterodimer of
Fos (c-Fos, Fos B, Fra-1, and Fra-2), Jun (c-Jun, Jun D, and
Jun B), and activating transcription factor (ATF-1 and
ATF-2) proteins [9].
Fra-1 (fosl1) is one of the main AP-1 family transcrip-
tion factors with diverse functions particularly in epithe-
lial cell growth, differentiation, and transformation.
Fra-1 contributes to creating Epithelial-to-mesenchymal
transition (EMT) and further carcinogenesis [9, 10]. an
inflammatory cytokine, like interleukin-6 (IL-6), poten-
tially triggers Fra-1 gene transcription by binding STAT3
to the promoter of Fra-1 gene in colorectal carcinoma
(CRC) cells [11]. In mice model, blocking of AP-1 tran-
scription factor has been shown to inhibit colonic
inflammation during DSS-induced colitis [12]. On a
cellular level, oxidative stress has been shown to induce
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IL-11 production via Fra-1 signalling [13] (Fig. 1). Like-
wise, Fra-1 along with Nuclear Factor Erythroid 2-related
Factor 2 (NRF2), motivates IL-11 production in extra elec-
trophiles environments [14].
IL-11, a member of the IL-6 family, is strongly expressed
in an oxidative stress condition [15]. IL-11 binds to IL-11
receptor alpha (IL-11Rα) on various cells including lung
and intestinal epithelial cells as well as osteoclast cell
surfaces. IL-11 are potentially capable of hematopoiesis,
repair mechanisms, bone development and carcinogenesis
[6, 15]. IL-11 and IL-6 activate STAT3 through GP130
signalling so that intestinal cells are highly regenerated
after damage [6]. IL-11 may be involved in inflammatory
responses and development of colitis-associated colorectal
cancer [16]. On the other hand, IL-11 can improve intact
intestinal barrier in mice model colitis by up-regulation of
TLR-2 in the colon [17].
In this study, we will examine the IL-11 protein amount
in the inflamed colonic tissue of the patients affected by
ulcerative colitis. However, this analysis was not particu-
larly applied in patient’s epithelial cells. Besides, Fra-1
gene expression and its relationship with IL-11 were con-
sidered in the following. In this paper, we demonstrate the
overexpression of Fra-1 gene is due to its transcription
factor as observed in mild UC patients and suggest that
IL-11 is elevated in inflamed colonic tissues.
Materials and methods
Sample collection and preparation
The study group comprised of 20 patients with UC and
20 healthy individuals as control (Table.1). All cases
were attended in Gastroenterology Unit of Hajar
hospital, Shahrekord, Iran, from January to May 2017.
Clinical information of the patients was collected based
on an opt query and medical files consisting of age, gen-
der, medical and surgical history, food habits, stress, dis-
ease severity and extension, colonoscopic and pathologic
records, treatment and hospitalizations. Disease activity
index for ulcerative colitis was evaluated by the combin-
ation of endoscopic and clinical scale [18]. The diagnosis
of UC was confirmed by the related clinical manifesta-
tions such as abdominal pain, chronic diarrhea, anal
bleeding, and histological criteria according to the Mon-
treal Classification [19]. Fourteen UC patients had a
mild proctosigmoiditis (inflammation was limited from
the colorectum distal to the splenic flexure/ erythema is
detected in the rectum and sigmoid, decreased friability
and vascular pattern/ Montreal class: E2). Six severe pa-
tients had consumed corticosteroid six months prior the
sampling date (Involvement extends proximal to the
splenic flexure/ Montreal class: E3). The control group
was selected among healthy individuals without any
immune-mediated diseases such as multiple sclerosis
and arthritis rheumatoid. These subjects were undergone
colonoscopy due to the screening for colorectal cancer
or polyp surveillance without inflammatory disease or
any medication. The study was approved by Shahrekord
University of Medical Sciences Ethics Committee. The
written consent was also obtained from all individuals in
the study.
Enzyme-linked immunosorbent assay
Two samples or colonic biopsies were taken from each
individual by a GI specialist. The biopsies were kept at
− 80 °C and the Fra-1 gene and IL-11 protein were
detected afterward. The samples’ protein were extracted
using an Abcam ELISA lysis buffer guide [20].
Fig. 1 The IL-11/fra-1 pathway that in colonic tissue of patients with UC is designed. Environmental effects trigger innate immune system to produce
ROS and inflammatory mediators. IL-11 can be released to reconstruct injury as a result of the activated IL-11/fra-1 pathway
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Briefly, we prepared extraction buffer by (100 mM
Tris, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 and
0.5% Sodium deoxycholate) and 1 mL of extraction buf-
fer pipetted to each tube. It was followed by adding
PMSF and Protease inhibitor cocktail to the tube and
homogenized one biopsy in each tube. The supernatant
of each sample was separated after 20 min centrifugation
at 13000 rpm at 4 °C. Total protein concentrations were
measured by Bradford protein assay and normalized
individually. All samples were evaluated in two repli-
cates. The limit of detection was 10 pg/mL. and of those
> 10 pg/mL as considered as positive. Quantification of
Human IL-11 protein Level was measured by means of
Abcam ELISA kit for human IL-11 (Abcam, England,
catalog number: ab100551), according to the manufac-
turer instructions.
RNA isolation and quantitative RT-PCR
Total RNA was extracted from biopsies using TRIzol®
reagent (Invitrogen/Thermo Fisher Scientific, Inc., cata-
logue number. 15596026) For each sample, RNA con-
centration was determined by Thermo Scientific™
NanoDrop 2000 and stored at − 80 °C. For all samples,
260/280 ratio for samples was greater than 1.8. cDNAs
were synthesized using the RevertAid first-strand
cDNA synthesis kit (Thermo Scientific, K1622) with
1.5 μg of RNA in a reaction volume of 20 μL after
DNaseI (Fermentas EN0521) digestion. The quantifica-
tion of mRNA was performed using RT-PCR on a
Rotor-Gene RG-300 (Corbett Research, Sydney, AU)
and the SYBR Green Real-time PCR Master Mix Kit
(TAKARA, Japan, catalog number. RR820Q) were used
according to the protocol provided by the manufac-
turer. The primers were designed by Primer3.0 (http://
bioinfo.ut.ee/primer3-0.4.0) web-based server (Table.2).
We ensured that there were no Single Nucleotide Poly-
phemus in the genomic region corresponding to the 3′
ends of primers by looking through the dbSNP data-
base. This was done to evaluate the ability of generating
unique primers for our experiment. The primers speci-
ficity was confirmed and verified by the in-silico-PCR
tool in UCSC genome browser and Primer blast of
NCBI genome browser. Thermal cycling was initiated
with a first denaturation step at 95 C for a duration of
5 min and was followed by 38 cycles of 95 °C for 15 s,
61 °C for 20s and 72 °C for 25 s. Melting curve analysis
was used to confirm amplification specificities. Gene
expression was normalized to internal controls and
fold changes were calculated using relative quantifica-
tion (2−ΔΔCq).
Statistical analysis
All data were presented as mean ± SD and were evalu-
ated by SPSS19.0 (SPSS Inc., Chicago, IL, USA) and
GraphPad Prism software version 5.0 (GraphPad Soft-
ware, La Jolla, CA, USA). The distribution of data was
normal and the relationship between age of subjects and
groups was addressed with the Fischer exact test. Un-
paired t-Test was used to compare the two groups and
multiple comparisons were done by Tukey post hoc.
Pearson’s correlation analysis was used to estimate the
correlations between Fra-1 gene expression and IL-11
protein amount. Differences calculating in P-values
< 0.05 were considered to be statistically significant.
Table 1 Demographic information of the patients
Control Mild colitis Severe colitis P-value
Age 33.81 ± 8.85 35.43 ± 9.55 32.00 ± 9.06 0.729
Gender (M/F) 11/9 7/7 3/3 0.913
Smoking % 9.5% 21.4% 46.7% 0.019*
Habitat (Rural/Urban) 2/19 4/10 3/3 0.078
Previous Abdominal Surgery 19% 64.3% 50% 0.295
Montreal Classification of Extent (E index) E1: 3 E2: 11 E3: 6 0.674
Montreal Classification of Severity (S index) S1: 8 S2:4 S3: 6 0.756
*= The number of smoking people were reach statistical significance (P- value = 0.019)
E1 ulcerative proctitis, E2 left-sided UC (distal to splenic flexure), E3: extensive (proximal to splenic flexure)
S0 clinical remission, S1: mild UC, S2 moderate UC, S3: severe UC
Table 2 Primer sequences used for real time PCR quantifications
Gene Primer sequences (5′-3′) Tm (°C) Amplicon Size (bp)
fra-1 F: -5́ TGACCACACCCTCCCTAACTC -3́ 60.83 100 bp
R: -5́ CTGCTGCTACTCTTGCGATGA -3́ 60.47
GAPDH F: -5́ ACAGTCAGCCGCATCTTC -3́ 57.39 169 bp
R: -5́ CTCCGACCTTCACCTTCC -3́ 57.66
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Results
Fra-1 gene expression increased in mild colitis
We evaluated the mRNA level of Fra-1 by RT-PCR in
the inflamed colonic biopsy of mild and severe UC
patients. In this experiment, Fra-1 gene expression in
UC patients was compared with control samples (taken
from non-inflamed colonic mucosa). As shown in the
Fig. 2a, the mean Fra-1 gene expression in UC samples
seem to be more than control samples and the explana-
tory variables were statistically significant (P-value =
0.027). The gene expression of Fra-1 in mild UC patients
is twofold higher than the control group (P-value =
0.010, Fig. 2b). Moreover, the Fra-1 mRNA level was
remarkably elevated in mild patients compared to that
of severe (P-value = 0.031, Fig. 2b). Surprisingly, the
comparison of Fra-1 gene expression between severe
and control biopsies did not show any statistical signifi-
cation (P-value > 0.05, Fig. 2b).
Expression of IL-11 protein is declined in severe colitis
Recent investigations have suggested that IL-11 gene
expression decreased with an extended intensity of
inflammation [21], but our data somehow conflicting.
IL-11 protein level was measured by ELISA method in
colonic biopsies of UC patients. IL-11 protein concentra-
tions in severe patients were dramatically declined (mean
± SD = 17.181 ± 3.96 pg/ml). On the other hand, the
concentration for mild patients and controls had a much
wider increase, at about 52.56 ± 19.62 and 34.28 ±
9.04 pg/ml, respectively (Fig. 3b). Accordingly, statis-
tical analysis showed meaningful differences between
mild UC and control’s group (P-value = 0.008), severe
UC and control (P-value = 0.042), and mild UC and severe
UC (P-value < 0.001) (Fig. 3b). On the other hand, no dif-
ferences were found in IL-11 protein expression between
UC patients and controls (P-value > 0.05, Fig. 3a). Further-
more, the protein levels of IL-11 considerably correlated
with Fra-1 gene expression in patients. This analysis
indicates that increased Fra-1 gene expression results in
surging IL-11 in UC colonic biopsies (r = 0.704, Table 3).
Discussion
The destructive effects of ROS are highly connected to
cytokine responses involved in repairing intestinal injury
when the oxidative damage in the inflamed mucosa
correlates with IBD intensity [22]. The existence of
specific polymorphism, dinucleotide repeat of the
IL11.A1 allele, in IL-11 was significantly associated with
UC have been seen in various studies [23]. Making use
of recombinant human IL-11 able to maintain remission
phase in Crohn’s disease [24]. Nevertheless, there are
few different theories concerning the role that IL-11
plays to promote colitis into colorectal cancer while the
alleviating function of IL-11 in colitis has been detected
[16]. The direct effects of IL-11 can differentiate CD4+ T
cells into Th2 cells which is a dominant subset of T ef-
fectors in UC [25]. In other Th2-dominant inflammatory
diseases, like asthma, the high level of IL-11 has been
measured [26]. A previous study reported the decreasing
of IL-11 gene expression in mild and severe UC patients,
but did not assess IL-11 intestinal or serum protein
levels [21]. In contrast to this study, we detected an
enhanced IL-11 protein expression in mild UC. Some
investigations on mice showed that the protective and
restorative roles of IL-11 elevated when the murine
intestinal cells were exposed to radiation or chemical
Fig. 2 Fra-1 (fosl1) mRNA level was evaluated in 20 UC and 20 control mucosa. The data derived from the real-time PCR for human Fra-1 were
normalized versus GAPDH-as an inner gene control. a Increased level of Fra-1 mRNA was detected in the patient group (P-value = 0.027). b Similarly,
Fra-1 gene expression was dramatically overexpressed in endoscopic specimens in mild patients rather than in both severe patients and control. UC:
ulcerative colitis. F.C: Fold Change
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stresses. IL-11 was considered as a mucosal protective in
addition to retraining the apoptosis of mature entero-
cytes [27, 28]. Our data illustrated that Fra-1 gene
expression had a similar pattern with an expression of
the IL-11 protein. Furthermore, Fra-1 gene expression
in our analysis positively correlated with IL-11 expres-
sion in the mild patient group. Fra-1 factor is an essen-
tial mediator to induce IL-11 through oncogenic Ras
activation. The human pancreatic carcinoma cells
decreased serum induce-IL-11 in response to Fra-1
blocking siRNA even after making use of Ras activator
[29].Both Fra-1 and IL-11 are relatively overexpressed in
oxidative stress condition. Extracellular signal-regulated
kinase2 (ERK2), which is stimulated by ROS components,
induces Fra-1 in retinal, liver and CRC cell [10, 13, 30].
Pro-inflammatory cytokines such as IL-18 and IL-6 are
able to stimulate MAPK pathway leading to increasing
epithelium-derived IL-11 in DSS mice model [11, 31]. It
has been elucidated that the targeting AP-1 factor through
oligodeoxynucleotide (ODN) therapy reduces histological
inflammation in DSS-induced experimental murine colitis
[12]. Oxidative stress, along with Fra-1 factor, can activate
other transcription factors including NRF-2 and HIF-1
that up-regulate IL-11 transcription [32]. Mothers against
decapentaplegic homolog 3 (SMAD3) is affected by
microenvironment in UC patients and is altered into
pSmad3L/C form. Accordingly, SMAD3 and Runt-related
transcription factor 2 (RUNX2) bind to the IL-11 pro-
moter in order to transcript IL-11 gene [33, 34]. These
factors lead to the production of IL-11 protein in mild
UC. However, IL-11 and Fra-1 expression are decreased
in severe UC mucosa remains unclear. Our observations
suggest the possibility that consuming corticosteroid drug
in severe UC patients may inhibit Fra-1 and IL-11 in the
following. In fact the loss of AP-1 and NF-kB factors as a
result of corticosteroids effects consequently inhibits
IL-11 production [35, 36]. On the other hand, transform-
ing Growth Factor beta (TGF-β1) which is an essential
co-factors with Fra-1 to induce IL-11, is significantly
decreased in active form of UC patients [37]. Otherwise,
further investigations are needed to characterize molecu-
lar mechanisms responsible for IL-11 and Fra-1 gene
expression. In addition, specific cells that produce IL-11 in
UC intestine should be clearly detected. In sum, we dem-
onstrated that IL-11 protein expression is increased in the
colonic biopsy of mild UC patients. Our data suggest that
epithelial cells under oxidative stress trigger Fra-1 and
IL-11 expression in the following.
Conclusion
The present findings demonstrate that Fra-1 gene ex-
pression and protein levels of IL-11 could be influenced
by ROS in intestine epithelial cells. In conclusion, Fra-1
gene expression and IL-11 protein amounts are in-
creased in the colonic biopsy of mild UC patients. This
seems to be a repairing and protective mechanism
against injury in UC patients; however, more reliable re-
search will be carried out to shed light on the reasons
why IL-11 is declined in severe UC.
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